HC Wainwright Forecasts FibroGen FY2026 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for FibroGen in a research note issued on Tuesday, December 17th. HC Wainwright analyst M. Keller expects that the biopharmaceutical company will post earnings per share of ($0.56) for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

FGEN has been the subject of several other research reports. StockNews.com started coverage on shares of FibroGen in a report on Monday. They issued a “hold” rating for the company. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

NASDAQ FGEN opened at $0.35 on Wednesday. The stock has a market cap of $35.64 million, a price-to-earnings ratio of -0.29 and a beta of 0.82. The business has a 50 day simple moving average of $0.35 and a 200 day simple moving average of $0.57. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same period in the previous year, the firm posted ($0.52) earnings per share.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares in the last quarter. FMR LLC boosted its holdings in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in FibroGen in the third quarter valued at $307,000. Point72 DIFC Ltd increased its stake in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.